Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China · Delayed Price · Currency is CNY 7.57
+0.02 (0.26%)
Feb 4, 2026, 3:04 PM CST
SHE:002581 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 252.99 | 355.66 | 425.78 | 356.18 | 397.44 | 274.72 |
Other Revenue | 4.75 | 4.75 | 4.01 | 0.9 | 5.27 | 2.11 |
| 257.74 | 360.41 | 429.79 | 357.08 | 402.71 | 276.83 | |
Revenue Growth (YoY) | -36.54% | -16.14% | 20.36% | -11.33% | 45.47% | -51.23% |
Cost of Revenue | 158.45 | 87.67 | 93.29 | 76.64 | 85.83 | 54.88 |
Gross Profit | 99.3 | 272.74 | 336.5 | 280.44 | 316.88 | 221.95 |
Selling, General & Admin | 261.25 | 336.65 | 453.3 | 426.21 | 477.76 | 414.31 |
Research & Development | 22.96 | 25.37 | 59.8 | 27.29 | 38.44 | 49.3 |
Other Operating Expenses | 6.41 | 6.31 | 6.78 | 6.24 | 6.83 | 6.63 |
Operating Expenses | 293.69 | 363.6 | 492.32 | 456.02 | 520.83 | 482.29 |
Operating Income | -194.4 | -90.86 | -155.81 | -175.57 | -203.95 | -260.34 |
Interest Expense | -0.2 | -0.2 | -9.06 | -9.41 | -6.88 | -25.43 |
Interest & Investment Income | 24.72 | 67.28 | 174.46 | 3.02 | 3.75 | 17.2 |
Earnings From Equity Investments | - | - | - | 217.45 | 471.94 | 109.61 |
Currency Exchange Gain (Loss) | 0 | 0 | - | 0 | -0.01 | -0.01 |
Other Non Operating Income (Expenses) | -0.47 | 0.3 | -9.88 | 0.22 | -6.68 | -5.38 |
EBT Excluding Unusual Items | -170.34 | -23.49 | -0.29 | 35.72 | 258.18 | -164.34 |
Impairment of Goodwill | - | - | - | - | - | -20.43 |
Gain (Loss) on Sale of Investments | -18.65 | -18.65 | - | - | - | - |
Gain (Loss) on Sale of Assets | 8.19 | 1.16 | -6.33 | 0.05 | -0.15 | -22.69 |
Asset Writedown | -72.6 | -69.64 | -293.88 | -13.61 | -0.48 | -6.59 |
Legal Settlements | -33.27 | -33.27 | - | -15.49 | - | - |
Other Unusual Items | 10.16 | -2.29 | -12.76 | 6.05 | 21.05 | 12.29 |
Pretax Income | -276.51 | -146.18 | -313.25 | 12.72 | 278.6 | -201.76 |
Income Tax Expense | -15.68 | -3.34 | 8.89 | 13.58 | -0.09 | -3.59 |
Earnings From Continuing Operations | -260.84 | -142.84 | -322.14 | -0.86 | 278.69 | -198.18 |
Minority Interest in Earnings | 40.09 | 5.52 | -10.32 | -13.82 | -7.69 | 2.24 |
Net Income | -220.75 | -137.31 | -332.46 | -14.68 | 271 | -195.93 |
Net Income to Common | -220.75 | -137.31 | -332.46 | -14.68 | 271 | -195.93 |
Shares Outstanding (Basic) | 661 | 660 | 660 | 658 | 660 | 660 |
Shares Outstanding (Diluted) | 661 | 660 | 660 | 658 | 660 | 660 |
Shares Change (YoY) | 0.28% | 0.01% | 0.22% | -0.21% | -0.00% | 0.02% |
EPS (Basic) | -0.33 | -0.21 | -0.50 | -0.02 | 0.41 | -0.30 |
EPS (Diluted) | -0.33 | -0.21 | -0.50 | -0.02 | 0.41 | -0.30 |
Free Cash Flow | -297.97 | -15.56 | -40.82 | -85.95 | -106.86 | -49.19 |
Free Cash Flow Per Share | -0.45 | -0.02 | -0.06 | -0.13 | -0.16 | -0.07 |
Gross Margin | 38.52% | 75.67% | 78.30% | 78.54% | 78.69% | 80.18% |
Operating Margin | -75.42% | -25.21% | -36.25% | -49.17% | -50.64% | -94.04% |
Profit Margin | -85.65% | -38.10% | -77.35% | -4.11% | 67.29% | -70.78% |
Free Cash Flow Margin | -115.61% | -4.32% | -9.50% | -24.07% | -26.53% | -17.77% |
EBITDA | -173.66 | -49.7 | -87.43 | -110.63 | -144.38 | -200.66 |
EBITDA Margin | -67.38% | -13.79% | -20.34% | -30.98% | -35.85% | -72.48% |
D&A For EBITDA | 20.74 | 41.16 | 68.39 | 64.95 | 59.57 | 59.68 |
EBIT | -194.4 | -90.86 | -155.81 | -175.57 | -203.95 | -260.34 |
EBIT Margin | -75.42% | -25.21% | -36.25% | -49.17% | -50.64% | -94.04% |
Effective Tax Rate | - | - | - | 106.75% | - | - |
Revenue as Reported | 257.74 | 360.41 | 429.79 | 357.08 | 402.71 | 276.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.